Αρχική World News FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma World News FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Από Ogkologos - 5 Δεκεμβρίου, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... 18 Δεκεμβρίου, 2020 GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... 17 Σεπτεμβρίου, 2020 Lo que deben saber las personas con cáncer de mama y... 4 Ιανουαρίου, 2024 Will This Cancer Metastasize? Check Its “Stickiness” 6 Μαΐου, 2025 Φόρτωση περισσοτέρων HOT NEWS Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... How to Find Reliable and Affordable Transportation During Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly...